FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jay Cohn

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Physiology

Hemodynamics

Co-author Network

Publications

TOP 3
S M Saul; W Zhong; D A Duprez; G A Grandits; Jay N Cohn
Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: the DETECT Study.
Inder S Anand; Michael Kuskowski; Pieter Muntendam; Thomas S Rector; Aram Adourian; Jay N Cohn
Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
Jay N Cohn
Preventing heart failure: a critique of strategies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jay Cohn (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: S M Saul; W Zhong; D A Duprez; G A Grandits; Jay N Cohn
Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: the DETECT Study.
Journal of human hypertension 2013;27(6):362-7.
2013: Inder S Anand; Michael Kuskowski; Pieter Muntendam; Thomas S Rector; Aram Adourian; Jay N Cohn
Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
European journal of heart failure 2013;15(5):511-8.
2013: Jay N Cohn
Preventing heart failure: a critique of strategies.
Journal of cardiac failure 2013;19(4):211-3.
2012: Jay N Cohn; Daniel A Duprez
The problem with cardiovascular disease prevention guidelines.
Current treatment options in cardiovascular medicine 2012;14(6):571-4.
2012: Michael D Miedema; Thomas Knickelbine; Jay N Cohn; Ross F Garberich; Kevin J Graham; Timothy D Henry
Underuse of cardiovascular preventive pharmacotherapy in patients presenting with ST-elevation myocardial infarction.
American heart journal 2012;164(2):259-67.
2012: Anne L Taylor; Manuel Worcel; Susan Ziesche; W Tad Archambault; Jay N Cohn; Jalal K Ghali; Michael L Sabolinski; S William Tam
Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial.
Journal of cardiac failure 2012;18(8):600-6.
2012: Jay N Cohn; Gary S Francis
Stage B, a precursor of heart failure, part II.
Heart failure clinics 2012;8(2):xv.
2012: Jay N Cohn
What's in a name?
Journal of cardiac failure 2012;18(3):175.
2012: Serge Masson; Luigi Tavazzi; Gianni Tognoni; Tarcisio Vago; Inder Anand; Simona Barlera; Federico Bertocchi; Jay N Cohn; Chiara Favero; Roberto Latini; Aldo P Maggioni
Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials.
Circulation 2012;125(2):280-8.
2012: Jay N Cohn; Gary S Francis
Stage B, a pre-cursor of heart failure.
Heart failure clinics 2012;8(1):xvii-xviii.
2011: Jay N Cohn
Should the blood pressure or the blood vessel be the target of therapy?
Expert review of cardiovascular therapy 2011;9(11):1397-401.
2011: Jay N Cohn
Is activation of the renin-angiotensin system hazardous to your health?
European heart journal 2011;32(17):2096-7.
2011: Daniel A Duprez; Natalia D Florea; Gregory A Grandits; Caitlin K Hawthorne; Lynn Hoke; Wei Zhong; Jay N Cohn
Vascular and cardiac functional and structural screening to identify risk of future morbid events: preliminary observations.
Journal of the American Society of Hypertension : JASH 2011;5(5):401-9.
2010: Jay N Cohn
Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system.
Journal of applied physiology (Bethesda, Md. : 1985) 2010;109(6):2006-7.
2010: Jay N Cohn
Heart failure is preventable.
Current heart failure reports 2010;7(3):91-2.
2010: Jay N Cohn
Cardiovascular pharmacotherapy 2010: foreword.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2010;24(4):297.
2010: Jay N Cohn
Role of the renin-angiotensin system in cardiovascular disease.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2010;24(4):341-4.
2010: Jay N Cohn
President's Page: ISCP's educational goals.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2010;24(1):89.
2009: Peter Carson; S William Tam; Jalal K Ghali; W Tad Archambault; Anne Taylor; Jay N Cohn; Virginia M Braman; Manuel Worcel; Inder S Anand
Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial.
Journal of cardiac failure 2009;15(10):835-42.
2009: Jay N Cohn
The president's page: target response or target dose.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2009;23(4):337.
2009: Jay N Cohn
Conflicts of interest: to eliminate them or manage them.
Journal of cardiac failure 2009;15(5):375-6.
2009: Dennis M McNamara; S William Tam; Michael L Sabolinski; Page Tobelmann; Karen Janosko; Lakshmi Venkitachalam; Elizabeth Ofili; Clyde W Yancy; Arthur M Feldman; Jalal K Ghali; Anne L Taylor; Jay N Cohn; Manuel Worcel
Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial.
Journal of cardiac failure 2009;15(3):191-8.
2009: Jay N Cohn; Daniel J Wilson; Joel M Neutel; Mark Houston; Myron H Weinberger; Richard Grimm; David H G Smith; William Sun
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.
American journal of hypertension 2009;22(2):137-44.
2008: Jalal K Ghali; S William Tam; Michael L Sabolinski; Anne L Taylor; JoAnn Lindenfeld; Jay N Cohn; Manuel Worcel
Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial.
Journal of cardiac failure 2008;14(9):718-23.
2008: Jay N Cohn
Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
Nature clinical practice. Cardiovascular medicine 2008;5(9):526-7.
2008: Jay N Cohn; Daniel A Duprez
Time to foster a rational approach to preventing cardiovascular morbid events.
Journal of the American College of Cardiology 2008;52(5):327-9.
2008: Inder S Anand; Thomas S Rector; Michael Kuskowski; Sabu Thomas; N J Holwerda; Jay N Cohn
Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
Circulation. Heart failure 2008;1(1):34-42.
2008: Daniel A Duprez; Jay N Cohn
Identifying early cardiovascular disease to target candidates for treatment.
Journal of clinical hypertension (Greenwich, Conn.) 2008;10(3):226-31.
2008: Jay N Cohn; Jesse M Goldman
Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.
American journal of hypertension 2008;21(3):248-56.
2007: Lidia Staszewsky; Maylene Wong; Serge Masson; Simona Barlera; Elisa Carretta; Aldo P Maggioni; Inder S Anand; Jay N Cohn; Gianni Tognoni; Roberto Latini
Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
Journal of cardiac failure 2007;13(10):797-804.
2007: Roberto Latini; Serge Masson; Inder S Anand; Emil Missov; Marjorie Carlson; Tarcisio Vago; Laura Angelici; Simona Barlera; Giovanni Parrinello; Aldo P Maggioni; Gianni Tognoni; Jay N Cohn
Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.
Circulation 2007;116(11):1242-9.
2007: Jay N Cohn; S William Tam; Inder S Anand; Anne L Taylor; Michael L Sabolinski; Manuel Worcel
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.
Journal of cardiac failure 2007;13(5):331-9.
2007: Anne L Taylor; Susan Ziesche; Clyde W Yancy; Peter Carson; Keith Ferdinand; Malcolm Taylor; Kirkwood F Adams; Adeoye Y Olukotun; Elizabeth Ofili; S William Tam; Michael L Sabolinski; Manuel Worcel; Jay N Cohn
Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
Circulation 2007;115(13):1747-53.
2007: Mariantonietta Cicoira; Aldo P Maggioni; Roberto Latini; Simona Barlera; Elisa Carretta; Andras Janosi; Jordi Soler-Soler; Inder S Anand; Jay N Cohn
Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial.
European journal of heart failure 2007;9(4):397-402.
2007: Inder S Anand; S William Tam; Thomas S Rector; Anne L Taylor; Michael L Sabolinski; W Tad Archambault; Kirkwood F Adams; Adeoye Y Olukotun; Manuel Worcel; Jay N Cohn
Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial.
Journal of the American College of Cardiology 2007;49(1):32-9.
2007: Masood Gilani; Dan Kaiser; Chris W Bratteli; Cheryl Alinder; Scott Rajala; Alan J Bank; Jay N Cohn
Role of nitric oxide deficiency and its detection as a risk factor in pre-hypertension.
Journal of the American Society of Hypertension : JASH 2007;1(1):45-55.
2007: Jay N Cohn
Is it the blood pressure or the blood vessel?
Journal of the American Society of Hypertension : JASH 2007;1(1):5-16.
2007: Jay N Cohn
In memorium louis tobian.
Journal of the American Society of Hypertension : JASH 2007;1(1):3-4.
2007: Jalal K Ghali; S William Tam; Keith C Ferdinand; JoAnn Lindenfeld; Michael L Sabolinski; Anne L Taylor; Manuel Worcel; Charles L Curry; Jay N Cohn
Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2007;7(5):373-80.
2007: S William Tam; Michael L Sabolinski; Manuel Worcel; Milton Packer; Jay N Cohn
Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Clinical pharmacokinetics 2007;46(10):885-95.
2006: Anne L Taylor; JoAnn Lindenfeld; Susan Ziesche; Mary Norine Walsh; Judith E Mitchell; Kirkwood F Adams; S William Tam; Elizabeth Ofili; Michael L Sabolinski; Manuel Worcel; Jay N Cohn
Outcomes by gender in the African-American Heart Failure Trial.
Journal of the American College of Cardiology 2006;48(11):2263-7.
2006: Jay N Cohn
What is the role of angiotensin-receptor blockade in cardiovascular protection?
American heart journal 2006;152(5):859.e1-8.
2006: Dennis M McNamara; S William Tam; Michael L Sabolinski; Page Tobelmann; Karen Janosko; Anne L Taylor; Jay N Cohn; Arthur M Feldman; Manuel Worcel
Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial.
Journal of the American College of Cardiology 2006;48(6):1277-82.
2006: Jay N Cohn
Efficacy and safety in clinical trials in cardiovascular disease.
Journal of the American College of Cardiology 2006;48(3):430-3.
2006: Serge Masson; Roberto Latini; Inder S Anand; Tarcisio Vago; Laura Angelici; Simona Barlera; Emil Missov; Aldo Clerico; Gianni Tognoni; Jay N Cohn
Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.
Clinical chemistry 2006;52(8):1528-38.
2006: Maylene Wong; Lidia Staszewsky; Elisa Carretta; Simona Barlera; Roberto Latini; Yann-Tong Chiang; Robert Glazer; Jay N Cohn
Signs and symptoms in chronic heart failure: relevance of clinical trial results to point of care-data from Val-HeFT.
European journal of heart failure 2006;8(5):502-8.
2006: Serge Masson; Roberto Latini; Inder S Anand; Simona Barlera; Dianne Judd; Monica Salio; Francesco Perticone; Giampaolo Perini; Gianni Tognoni; Jay N Cohn
The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT).
Journal of cardiac failure 2006;12(5):375-80.
2006: Jay N Cohn; Wilson Colucci
Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology.
The American journal of cardiology 2006;97(10A):4F-12F.
2006: Jay N Cohn; Peter E Carson; Christopher O'Connor; Cristina Opasich; Ileana L Piña; Marino Scherillo; Gianfranco Sinagra; Lynne Warner-Stevenson; Felix E Tristani; Alberto Volpi
Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT.
Congestive heart failure (Greenwich, Conn.) 2006;12(3):127-31.
2006: Thomas S Rector; Inder S Anand; Jay N Cohn
Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life.
Journal of cardiac failure 2006;12(2):87-92.
2006: Roberto Latini; Serge Masson; Maylene Wong; Simona Barlera; Elisa Carretta; Lidia Staszewsky; Tarcisio Vago; Aldo P Maggioni; Inder S Anand; Lip B Tan; Gianni Tognoni; Jay N Cohn
Incremental prognostic value of changes in B-type natriuretic peptide in heart failure.
The American journal of medicine 2006;119(1):70.e23-30.
2005: Inder S Anand; Roberto Latini; Viorel G Florea; Michael A Kuskowski; Thomas S Rector; Serge Masson; STEFANO SIGNORINI; Paolo Mocarelli; Allen Hester; Robert Glazer; Jay N Cohn
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
Circulation 2005;112(10):1428-34.
2005: Inder S Anand; Michael A Kuskowski; Thomas S Rector; Viorel G Florea; Robert Glazer; Allen Hester; Yann-Tong Chiang; Nora Aknay; Aldo P Maggioni; Cristina Opasich; Roberto Latini; Jay N Cohn
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
Circulation 2005;112(8):1121-7.
2005: Jay N Cohn; Daniel A Duprez; Gregory A Grandits
Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment.
Hypertension 2005;46(1):217-20.
2005: Giuseppina Majani; Anna Giardini; Cristina Opasich; Robert Glazer; Allen Hester; Gianni Tognoni; Jay N Cohn; Luigi Tavazzi
Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial.
Journal of cardiac failure 2005;11(4):253-9.
2005: Aldo P Maggioni; Roberto Latini; Peter E Carson; Steven N Singh; Simona Barlera; Robert Glazer; Serge Masson; Elisabetta Cerè; Gianni Tognoni; Jay N Cohn
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
American heart journal 2005;149(3):548-57.
2004: Jay N Cohn
New therapeutic strategies for heart failure: left ventricular remodeling as a target.
Journal of cardiac failure 2004;10(6 Suppl):S200-1.
2004: Lawrence Baruch; Robert Glazer; Nora Aknay; Johan Vanhaecke; J Thomas Heywood; Inder S Anand; Henry Krum; Allen Hester; Jay N Cohn
Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
American heart journal 2004;148(6):951-7.
2004: Henry Krum; Peter Carson; Csaba Farsang; Aldo P Maggioni; Robert Glazer; Nora Aknay; Yann-Tong Chiang; Jay N Cohn
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
European journal of heart failure 2004;6(7):937-45.
2004: Anne L Taylor; Susan Ziesche; Clyde W Yancy; Peter Carson; Ralph D'Agostino; Keith Ferdinand; Malcolm Taylor; Kirkwood F Adams; Michael L Sabolinski; Manuel Worcel; Jay N Cohn
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
The New England journal of medicine 2004;351(20):2049-57.
2004: Daniel A Duprez; Dan Kaiser; Wayne Whitwam; Stanley Finkelstein; Andres Belalcazar; Robert Patterson; Stephen Glasser; Jay N Cohn
Determinants of radial artery pulse wave analysis in asymptomatic individuals.
American journal of hypertension 2004;17(8):647-53.
2004: Jay N Cohn
Introduction to surrogate markers.
Circulation 2004;109(25 Suppl 1):IV20-1.
2004: Maylene Wong; Lidia Staszewsky; Roberto Latini; Simona Barlera; Robert Glazer; Nora Aknay; Allen Hester; Inder S Anand; Jay N Cohn
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.
Journal of the American College of Cardiology 2004;43(11):2022-7.
2004: Jay N Cohn
The James B. Herrick Award Lecture. 2003. Clinical research: whose agenda is it?
Circulation 2004;109(19):2256-62.
2004: Roberto Latini; Serge Masson; Inder S Anand; Monica Salio; Allen Hester; Dianne Judd; Simona Barlera; Aldo P Maggioni; Gianni Tognoni; Jay N Cohn
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.
European heart journal 2004;25(4):292-9.
2004: Jay N Cohn; Stevo Julius; Joel M Neutel; Michael Weber; Prasad Turlapaty; Yannan Shen; Victor M Dong; Alicia Batchelor; Weinong Guo; Lagast Hjalmar
Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial.
American journal of hypertension 2004;17(2):134-8.
2004: Joel M Neutel; Michael A Weber; Stevo Julius; Jay N Cohn; Prasad Turlapaty; Yannan Shen; Weinong Guo; Alicia Batchelor; Lagast Hjalmar
Clinical experience with perindopril in elderly hypertensive patients: a subgroup analysis of a large community trial.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2004;4(5):335-41.
2004: Stevo Julius; Jay N Cohn; Joel M Neutel; Michael Weber; Prasad Turlapaty; Yannan Shen; Victor M Dong; Alicia Batchelor; Lagast Hjalmar
Antihypertensive utility of perindopril in a large, general practice-based clinical trial.
Journal of clinical hypertension (Greenwich, Conn.) 2004;6(1):10-7.
2003: Jay N Cohn
Beta-blockers for heart failure.
Journal of cardiac failure 2003;9(6):458.
2003: Jay N Cohn; Joseph Loscalzo; Joseph A Franciosa
Nitric oxide's role in heart failure: pathophysiology and treatment. Introduction.
Journal of cardiac failure 2003;9(5 Suppl Nitric Oxide):S197-8.
2003: Jay N Cohn; Inder S Anand; Roberto Latini; Serge Masson; Yann-Tong Chiang; Robert Glazer
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
Circulation 2003;108(11):1306-9.
2003: Jay N Cohn
Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failure.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2003;4(3):137-9.
2003: Elizabeth Grey; Chris W Bratteli; Stephen P Glasser; Cheryl Alinder; Stanley M Finkelstein; Bruce R Lindgren; Jay N Cohn
Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events.
American journal of hypertension 2003;16(4):265-9.
2003: Inder S Anand; Lloyd Fisher; Yann-Tong Chiang; Roberto Latini; Serge Masson; Aldo P Maggioni; Robert Glazer; Gianni Tognoni; Jay N Cohn
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
Circulation 2003;107(9):1278-83.
2002: Jay N Cohn
Global structural ventricular remodeling: summation.
Journal of cardiac failure 2002;8(6 Suppl):S269-70.
2002: Roberto Latini; Serge Masson; Inder S Anand; Dianne Judd; Aldo P Maggioni; Yann-Tong Chiang; Maurizio Bevilacqua; Monica Salio; Paola Cardano; Peter H J M Dunselman; Nicolaas J Holwerda; Gianni Tognoni; Jay N Cohn
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Circulation 2002;106(19):2454-8.
2002: Jay N Cohn
Lessons learned from the valsartan- heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure.
The American journal of cardiology 2002;90(9):992-3.
2002: Aldo P Maggioni; Inder Anand; Sidney O Gottlieb; Roberto Latini; Gianni Tognoni; Jay N Cohn
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
Journal of the American College of Cardiology 2002;40(8):1414-21.
2002: Maylene Wong; Lidia Staszewsky; Roberto Latini; Simona Barlera; Alberto Volpi; Yann-Tong Chiang; Raymond L Benza; Sidney O Gottlieb; Thomas D Kleemann; Franco Rosconi; Pieter M Vandervoort; Jay N Cohn
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.
Journal of the American College of Cardiology 2002;40(5):970-5.
2002: Anne L Taylor; Jay N Cohn; Manuel Worcel; Joseph A Franciosa
The African-American Heart Failure Trial: background, rationale and significance.
Journal of the National Medical Association 2002;94(9):762-9.
2002: Joseph A Franciosa; Anne L Taylor; Jay N Cohn; Clyde W Yancy; Susan Ziesche; Adeoye Y Olukotun; Elizabeth Ofili; Keith Ferdinand; Joseph Loscalzo; Manuel Worcel
African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology.
Journal of cardiac failure 2002;8(3):128-35.
2002: Carl V Leier; Marc A Silver; Michael W Rich; Eric Eichhorn; Michael B Fowler; Thomas D Giles; David E Johnstone; Thierry H Le Jemtel; Justine S Lachmann; T Barry Levine; Paul W Armstrong; William G Dec; Mariell Jessup; Jonathan G Howlett; Ray E Hershberger; Jay N Cohn; Kirkwood F Adams; Wilson S Colucci; Lynne Warner-Stevenson; Jeffrey D Hosenpud; Michael R Bristow; Ileana Pina; Kenneth L Baughman; philip binkley; Hector O Ventura; Gary S Francis; Michel White; Leslie W Miller; Brandy Berry; Emil Missov
Nuggets, pearls, and vignettes of master heart failure clinicians. Part 4--treatment.
Congestive heart failure (Greenwich, Conn.) 2002;8(2):98-124.
2001: Jay N Cohn; Gianni Tognoni
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
The New England journal of medicine 2001;345(23):1667-75.
2001: A Beltran; GE McVeigh; D Morgan; Stephen P Glasser; Joel M Neutel; M Weber; Stanley M Finkelstein; Jay N Cohn
Arterial compliance abnormalities in isolated systolic hypertension.
American journal of hypertension 2001;14(10):1007-11.
2001: Jay N Cohn
Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making.
American journal of hypertension 2001;14(8 Pt 2):258S-263S.
2001: Jay N Cohn
New approaches to screening for vascular and cardiac risk.
American journal of hypertension 2001;14(6 Pt 2):218S-220S.
2001: Clyde W Yancy; Michael B Fowler; WS Colucci; Edward M Gilbert; Michael R Bristow; Jay N Cohn; Mary Ann Lukas; ST Young; Milton Packer
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.
The New England journal of medicine 2001;344(18):1358-65.
2001: Michael B Fowler; Montserrat Vera-Llonch; Gerry Oster; Michael R Bristow; Jay N Cohn; WS Colucci; Edward M Gilbert; Mary Ann Lukas; M J Lacey; RE Richner; ST Young; Milton Packer
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.
Journal of the American College of Cardiology 2001;37(6):1692-9.
2001: Donna K Arnett; Stephen P Glasser; GE McVeigh; Ronald J Prineas; S Finklestein; R Donahue; Jay N Cohn; Alan R Sinaiko
Blood pressure and arterial compliance in young adults: the Minnesota Children's Blood Pressure Study.
American journal of hypertension 2001;14(3):200-5.
2001: Jay N Cohn
Left ventricle and arteries: structure, function, hormones, and disease.
Hypertension 2001;37(2 Pt 2):346-9.
2000: Jay N Cohn; Gianni Tognoni; Robert Glazer; D Spormann
Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators.
European journal of heart failure 2000;2(4):439-46.
2000: Steven E Reis; Richard Holubkov; J B Young; Bill G White; Jay N Cohn; Arthur M Feldman
Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies.
Journal of the American College of Cardiology 2000;36(2):529-33.
2000: John M Nicklas; Jay N Cohn; Bertram Pitt
What does ATLAS really tell us about "high" dose angiotensin-converting enzyme inhibition in heart failure?
Journal of cardiac failure 2000;6(2):165-8.
2000: R F Smith; T Germanson; Dianne Judd; M Wong; Susan Ziesche; Inder S Anand; W. Robert Taylor; Jay N Cohn
Plasma norepinephrine and atrial natriuretic peptide in heart failure: influence of felodipine in the third Vasodilator Heart Failure Trial. V-HeFT III investigators.
Journal of cardiac failure 2000;6(2):97-107.
2000: M Wong; T Germanson; W. Robert Taylor; I S Cohen; G Perry; Lawrence Baruch; P Deedwania; B Lopez; Jay N Cohn
Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change.
Journal of cardiac failure 2000;6(1):19-28.
2000: Jay N Cohn; R Ferrari; N Sharpe
Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.
Journal of the American College of Cardiology 2000;35(3):569-82.
1999: Jay N Cohn
Vascular wall function as a risk marker for cardiovascular disease.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1999;17(5):S41-4.
1999: Peter Carson; Susan Ziesche; G Johnson; Jay N Cohn
Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
Journal of cardiac failure 1999;5(3):178-87.
1999: Jay N Cohn; Gianni Tognoni; Robert Glazer; D Spormann; Allen Hester
Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.
Journal of cardiac failure 1999;5(2):155-60.
1999: GE McVeigh; Chris W Bratteli; DJ Morgan; C M Alinder; Stephen P Glasser; Stanley M Finkelstein; Jay N Cohn
Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance.
Hypertension 1999;33(6):1392-8.
1999: Lawrence Baruch; Inder S Anand; I S Cohen; Susan Ziesche; Dianne Judd; Jay N Cohn
Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Circulation 1999;99(20):2658-64.
1999: Jay N Cohn
Pathophysiologic and prognostic implications of measuring arterial compliance in hypertensive disease.
Progress in cardiovascular diseases 1999;41(6):441-50.
1999: B Tian; WC Carlyle; W G Weigold; KM McDonald; DL Judd; CA Toher; D C Homans; Jay N Cohn
Localization of changes in beta-actin expression in remodeled canine myocardium.
Journal of molecular and cellular cardiology 1999;31(4):751-60.
1999: Jay N Cohn
Prevention of heart failure.
Cardiology 1999;92 Suppl 1():22-5; discussion 26-8.
1999: Jay N Cohn
Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial.
Cardiology 1999;91 Suppl 1():19-22.
1998: Jay N Cohn; S O Goldstein; Barry H Greenberg; B H Lorell; Robert Bourge; Brian E Jaski; S O Gottlieb; Frank A McGrew; David L DeMets; B G White
A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
The New England journal of medicine 1998;339(25):1810-6.
1998: KM McDonald; A D'Aloia; T Parrish; J Mock; KM Hauer; A E Stillman; Jay N Cohn
Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition.
Journal of cardiac failure 1998;4(3):203-12.
1998: Jay N Cohn
Beta-blockers in heart failure.
European heart journal 1998;19 Suppl F():F52-5.
1998: Stephen P Glasser; Donna K Arnett; GE McVeigh; Stanley M Finkelstein; A K Bank; DJ Morgan; Jay N Cohn
The importance of arterial compliance in cardiovascular drug therapy.
Journal of clinical pharmacology 1998;38(3):202-12.
1998: Jay N Cohn
Evaluating pathophysiologic processes rather than clinical end points in improving therapeutic practice.
Journal of cardiovascular pharmacology 1998;32 Suppl 3():S38-40.
1997: Jay N Cohn
Overview of the treatment of heart failure.
The American journal of cardiology 1997;80(11A):2L-6L.
1997: KM McDonald; C Chu; G S Francis; WC Carlyle; DL Judd; KM Hauer; M Hartman; Jay N Cohn
Effect of delayed intervention with ACE-inhibitor therapy on myocyte hypertrophy and growth of the cardiac interstitium in the rat model of myocardial infarction.
Journal of molecular and cellular cardiology 1997;29(12):3203-10.
1997: Stephen P Glasser; Donna K Arnett; GE McVeigh; Stanley M Finkelstein; A J Bank; DJ Morgan; Jay N Cohn
Vascular compliance and cardiovascular disease: a risk factor or a marker?
American journal of hypertension 1997;10(10 Pt 1):1175-89.
1997: Jay N Cohn; Michael B Fowler; Michael R Bristow; WS Colucci; Edward M Gilbert; V Kinhal; Steven K Krueger; T Lejemtel; K A Narahara; Milton Packer; ST Young; Terry L Holcslaw; Mary Ann Lukas
Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.
Journal of cardiac failure 1997;3(3):173-9.
1997: Jay N Cohn; Susan Ziesche; R Smith; Inder S Anand; W B Dunkman; H Loeb; G Cintron; W Boden; Lawrence Baruch; P Rochin; L Loss
Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.
Circulation 1997;96(3):856-63.
1997: GE McVeigh; DJ Morgan; Stanley M Finkelstein; L A Lemay; Jay N Cohn
Vascular abnormalities associated with long-term cigarette smoking identified by arterial waveform analysis.
The American journal of medicine 1997;102(3):227-31.
1997: Jay N Cohn
Current concepts in the treatment of congestive heart failure.
Cardiology 1997;88 Suppl 2():2-6.
1996: Jay N Cohn
Prognosis in congestive heart failure.
Journal of cardiac failure 1996;2(4 Suppl):S225-9.
1996: Wilson S Colucci; Milton Packer; Michael R Bristow; Edward M Gilbert; Jay N Cohn; M B Fowler; S K Krueger; Ray E Hershberger; B F Uretsky; J A Bowers; J D Sackner-Bernstein; S T Young; T L Holcslaw; M A Lukas
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.
Circulation 1996;94(11):2800-6.
1996: Jay N Cohn
The management of chronic heart failure.
The New England journal of medicine 1996;335(7):490-8.
1996: Jay N Cohn
Left ventricular dysfunction and heart failure. Mechanistic and therapeutic distinctions.
Clinical and experimental hypertension (New York, N.Y. : 1993) 1996;18(3-4):559-68.
1996: WC Carlyle; CA Toher; J R Vandervelde; KM McDonald; D C Homans; Jay N Cohn
Changes in beta-actin mRNA expression in remodeling canine myocardium.
Journal of molecular and cellular cardiology 1996;28(1):53-63.
1995: Jay N Cohn
Structural changes in cardiovascular disease.
The American journal of cardiology 1995;76(15):34E-37E.
1995: Jay N Cohn
A symposium: from hypertension to heart failure: endothelial dysfunction and structural changes in cardiovascular disease. Introduction.
The American journal of cardiology 1995;76(15):1E-2E.
1995: Jay N Cohn; S Finkelstein; GE McVeigh; D Morgan; L LeMay; J Robinson; J Mock
Noninvasive pulse wave analysis for the early detection of vascular disease.
Hypertension 1995;26(3):503-8.
1995: Jay N Cohn
Critical review of heart failure: the role of left ventricular remodeling in the therapeutic response.
Clinical cardiology 1995;18(9 Suppl 4):IV4-12.
1995: KM McDonald; J Mock; A D'Aloia; T Parrish; KM Hauer; G Francis; A Stillman; Jay N Cohn
Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis.
Circulation 1995;91(7):2043-8.
1995: Susan Ziesche; T S Rector; Jay N Cohn
Interobserver discordance in the classification of mechanisms of death in studies of heart failure.
Journal of cardiac failure 1995;1(2):127-32.
1995: Jay N Cohn
Plasma norepinephrine and mortality.
Clinical cardiology 1995;18(3 Suppl I):I9-12.
1995: G S Francis; K McDonald; C Chu; Jay N Cohn
Pathophysiologic aspects of end-stage heart failure.
The American journal of cardiology 1995;75(3):11A-16A.
1994: KM McDonald; M Garr; P F Carlyle; G S Francis; KM Hauer; D W Hunter; T Parish; A Stillman; Jay N Cohn
Relative effects of alpha 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog.
Circulation 1994;90(6):3034-46.
1994: KM McDonald; T Rector; P F Carlyle; G S Francis; Jay N Cohn
Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage.
Journal of the American College of Cardiology 1994;24(7):1762-8.
1994: Jay N Cohn
Physiological rationale for co-treatment with diuretics in heart failure.
British heart journal 1994;72(2 Suppl):S63-7.
1994: Jay N Cohn
Has the problem of heart failure been solved?
The American journal of cardiology 1994;73(10):40C-43C.
1994: KM McDonald; M Yoshiyama; G S Francis; Kamil Ugurbil; Jay N Cohn; Jianyi Zhang
Myocardial bioenergetic abnormalities in a canine model of left ventricular dysfunction.
Journal of the American College of Cardiology 1994;23(3):786-93.
1994: T P Connelly; G S Francis; K J Williams; A M Beltran; Jay N Cohn
Interaction of intravenous atrial natriuretic factor with furosemide in patients with heart failure.
American heart journal 1994;127(2):392-9.
1994: Jay N Cohn
Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
Drugs 1994;47 Suppl 4():47-57; discussion 57-8.
1993: Jay N Cohn
Efficacy of vasodilators in the treatment of heart failure.
Journal of the American College of Cardiology 1993;22(4 Suppl A):135A-138A.
1993: Jay N Cohn
Nitrates versus angiotensin-converting enzyme inhibitors for congestive heart failure.
The American journal of cardiology 1993;72(8):21C-24C; discussion 24C-26C.
1993: W B Dunkman; Gary R Johnson; P E Carson; G Bhat; L Farrell; Jay N Cohn
Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI94-101.
1993: T S Rector; G Johnson; W B Dunkman; G Daniels; L Farrell; A Henrick; B Smith; Jay N Cohn
Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI71-7.
1993: Susan Ziesche; F R Cobb; Jay N Cohn; G Johnson; F Tristani
Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI56-64.
1993: Jay N Cohn; Gary R Johnson; R Shabetai; H Loeb; F Tristani; T Rector; R Smith; R Fletcher
Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI5-16.
1993: G S Francis; Jay N Cohn; G Johnson; T S Rector; S Goldman; A Simon
Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI40-8.
1993: S Goldman; G Johnson; Jay N Cohn; G Cintron; R Smith; G Francis
Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI24-31.
1993: G Cintron; G Johnson; G Francis; F Cobb; Jay N Cohn
Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI17-23.
1993: P E Carson; Gary R Johnson; W B Dunkman; R D Fletcher; L Farrell; Jay N Cohn
The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group.
Circulation 1993;87(6 Suppl):VI102-10.
1993: Jay N Cohn
The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction.
Circulation 1993;87(6 Suppl):VI1-4.
1993: Jay N Cohn
Post-MI remodeling.
Clinical cardiology 1993;16(5 Suppl 2):II21-4.
1993: T S Rector; Spencer Kubo; Jay N Cohn
Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo.
The American journal of cardiology 1993;71(12):1106-7.
1993: G S Francis; KM McDonald; Jay N Cohn
Neurohumoral activation in preclinical heart failure. Remodeling and the potential for intervention.
Circulation 1993;87(5 Suppl):IV90-6.
1993: KM McDonald; G S Francis; J Matthews; D Hunter; Jay N Cohn
Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog.
Journal of the American College of Cardiology 1993;21(2):514-22.
1993: GE McVeigh; Stanley M Finkelstein; Jay N Cohn
Assessment of arterial compliance in hypertension.
Current opinion in nephrology and hypertension 1993;2(1):82-6.
1992: Jay N Cohn
Pharmacologic mechanisms of nitrates in myocardial ischemia.
The American journal of cardiology 1992;70(17):38G-42G.
1992: T S Rector; Jay N Cohn
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
American heart journal 1992;124(4):1017-25.
1992: Jay N Cohn
Mechanisms of action and efficacy of nitrates in heart failure.
The American journal of cardiology 1992;70(8):88B-92B.
1992: Jay N Cohn; Stanley M Finkelstein
Abnormalities of vascular compliance in hypertension, aging and heart failure.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1992;10(6):S61-4.
1992: Stanley M Finkelstein; Jay N Cohn
First- and third-order models for determining arterial compliance.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1992;10(6):S11-4.
1992: KM McDonald; T Parrish; P Wennberg; A E Stillman; G S Francis; Jay N Cohn; D Hunter
Rapid, accurate and simultaneous noninvasive assessment of right and left ventricular mass with nuclear magnetic resonance imaging using the snapshot gradient method.
Journal of the American College of Cardiology 1992;19(7):1601-7.
1992: KM McDonald; G S Francis; P F Carlyle; KM Hauer; J Matthews; D W Hunter; Jay N Cohn
Hemodynamic, left ventricular structural and hormonal changes after discrete myocardial damage in the dog.
Journal of the American College of Cardiology 1992;19(2):460-7.
1991: Jay N Cohn
Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure.
Herz 1991;16 Spec No 1():267-71.
1991: Jay N Cohn; G Johnson; Susan Ziesche; F Cobb; G Francis; F Tristani; R Smith; W B Dunkman; H Loeb; M Wong
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
The New England journal of medicine 1991;325(5):303-10.
1991: GE McVeigh; D E Burns; Stanley M Finkelstein; KM McDonald; J E Mock; W Feske; P F Carlyle; John M Flack; R Grimm; Jay N Cohn
Reduced vascular compliance as a marker for essential hypertension.
American journal of hypertension 1991;4(3 Pt 1):245-51.
1991: Jay N Cohn
Future directions in vasodilator therapy for heart failure.
American heart journal 1991;121(3 Pt 1):969-74.
1990: S H Kubo; T S Rector; S M Heifetz; H Sato; Jay N Cohn
Atrial natriuretic factor attenuates sympathetic reflexes during lower body negative pressure in normal men.
Journal of cardiovascular pharmacology 1990;16(6):881-9.
1990: Jay N Cohn
Mechanisms in heart failure and the role of angiotensin-converting enzyme inhibition.
The American journal of cardiology 1990;66(11):2D-6D.
1990: P F Carlyle; Jay N Cohn
Systemic and regional hemodynamic effects of alpha-adrenoceptor blockade in chronic left ventricular dysfunction in the conscious dog.
American heart journal 1990;120(3):619-24.
1990: Jay N Cohn
Nitrates are effective in the treatment of chronic congestive heart failure: the protagonist's view.
The American journal of cardiology 1990;66(4):444-6.
1990: Jay N Cohn
Abnormalities of peripheral sympathetic nervous system control in congestive heart failure.
Circulation 1990;82(2 Suppl):I59-67.
1990: P Carson; P Carlyle; T S Rector; Jay N Cohn
Cardiovascular and neurohormonal effects of atrial natriuretic peptide in conscious dogs with and without chronic left ventricular dysfunction.
Journal of cardiovascular pharmacology 1990;16(2):305-11.
1990: Jay N Cohn
Neuroendocrine activation after acute myocardial infarction.
The American journal of cardiology 1990;65(19):28I-31I.
1990: Jay N Cohn
Hepatocirculatory failure: diverse pathogeneses deserve diverse therapies.
Hepatology (Baltimore, Md.) 1990;11(3):510-1.
1990: KM McDonald; P F Carlyle; J Matthews; KM Hauer; T Elbers; D Hunter; Jay N Cohn
Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition.
Transactions of the Association of American Physicians 1990;103():229-35.
1989: S H Kubo; T S Rector; S M Heifetz; Jay N Cohn
Alpha 2-receptor-mediated vasoconstriction in patients with congestive heart failure.
Circulation 1989;80(6):1660-7.
1989: Jay N Cohn
Sympathetic nervous system activity and the heart.
American journal of hypertension 1989;2(12 Pt 2):353S-356S.
1989: Jay N Cohn
Unloading the failing heart. Previous experience and future directions.
American journal of hypertension 1989;2(9):736-9.
1989: Jay N Cohn
Left ventricular function after myocardial infarction.
Journal of cardiovascular pharmacology 1989;14 Suppl 9():S55-8.
1989: Jay N Cohn
The sympathetic nervous system in heart failure.
Journal of cardiovascular pharmacology 1989;14 Suppl 5():S57-61.
1988: Jay N Cohn
Current therapy of the failing heart.
Circulation 1988;78(5 Pt 1):1099-107.
1988: Stanley M Finkelstein; V R Collins; Jay N Cohn
Arterial vascular compliance response to vasodilators by Fourier and pulse contour analysis.
Hypertension 1988;12(4):380-7.
1988: Jay N Cohn
Is neurohormonal activation deleterious to the long-term outcome of patients with congestive heart failure? III. Antagonist's viewpoint.
Journal of the American College of Cardiology 1988;12(2):554-8.
1988: Jay N Cohn; T S Rector
Prognosis of congestive heart failure and predictors of mortality.
The American journal of cardiology 1988;62(2):25A-30A.
1987: F E Tristani; C V Hughes; D G Archibald; L M Sheldahl; Jay N Cohn; R Fletcher
Safety of graded symptom-limited exercise testing in patients with congestive heart failure.
Circulation 1987;76(6 Pt 2):VI54-8.
1987: Jay N Cohn
Role of nitrates in congestive heart failure.
The American journal of cardiology 1987;60(15):39H-43H.
1987: M T Olivari; T Barry Levine; W S Ring; A Simon; Jay N Cohn
Normalization of sympathetic nervous system function after orthotopic cardiac transplant in man.
Circulation 1987;76(5 Pt 2):V62-4.
1987: Jay N Cohn
Role of drugs for systemic hypertension and their effect on the heart.
The American journal of cardiology 1987;60(12):72G-74G.
1987: Jay N Cohn; D G Archibald; G S Francis; Susan Ziesche; J A Franciosa; W E Harston; F E Tristani; W B Dunkman; W Jacobs; K H Flohr
Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.
Circulation 1987;75(5 Pt 2):IV49-54.
1987: J Mock; S M Finkelstein; J Eaton; G Hatfield; Jay N Cohn
Vascular compliance changes in hypertensive dogs during nitroprusside infusion as measured by pulse-contour-analysis.
Biomedical sciences instrumentation 1987;23():77-82.
1986: Jay N Cohn; D G Archibald; Susan Ziesche; J A Franciosa; W E Harston; F E Tristani; W B Dunkman; W Jacobs; G S Francis; K H Flohr
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
The New England journal of medicine 1986;314(24):1547-52.
1985: T S Rector; P F Carlyle; Jay N Cohn
Reduced atrial natriuretic factor after ligation of the left coronary artery in rats.
American heart journal 1985;110(6):1197-9.
1985: Stanley M Finkelstein; Jay N Cohn; V R Collins; P F Carlyle; W J Shelley
Vascular hemodynamic impedance in congestive heart failure.
The American journal of cardiology 1985;55(4):423-7.
1983: J A Franciosa; M Wilen; Susan Ziesche; Jay N Cohn
Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy.
The American journal of cardiology 1983;51(5):831-6.
1982: Jay N Cohn; J A Franciosa; G S Francis; D Archibald; F Tristani; R Fletcher; A Montero; G Cintron; J Clarke; D Hager; R Saunders; F Cobb; R Smith; H Loeb; H Settle
Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study.
The New England journal of medicine 1982;306(19):1129-35.
1980: L R Zobel; Stanley M Finkelstein; P F Carlyle; Jay N Cohn
Pressure pulse contour analysis in determining the effect of vasodilator drugs on vascular hemodynamic impedance characteristics in dogs.
American heart journal 1980;100(1):81-8.